Table 1.

Characteristics of study population during NDB followup (n = 264).

VariableMedian (IQR) or %
Age, yrs57.2 (50.1–64.4)
Disease duration, yrs10.4 (4.3–23.5)
Time from clinical trial closure, yrs0.8 (0.5–1.4)
Male, %17.0
Study treatment, %100.0
Prednisone, %30.7
Methotrexate, %68.2
Leflunomide, %3.4